Article in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors at 5 institutions in 2 countries.
Hoda Younes IbrahemClinical Research Department at Giza Health Affairs Directorate, Ministry of Health and Population, Giza P.O. Box 12511, Egypt.ORCID 0000-0002-9698-7641
Doaa Hamdy AlyClinical Research Department at Giza Health Affairs Directorate, Ministry of Health and Population, Giza P.O. Box 12511, Egypt.ORCID 0000-0003-1495-6620
Ahmed E Abou WardaClinical Pharmacy Department, Faculty of Pharmacy, October 6 University, Giza P.O. Box 12585, Egypt.ORCID 0000-0003-4434-6217
Raghda Mamdouh YoussefClinical Research Department at Giza Health Affairs Directorate, Ministry of Health and Population, Giza P.O. Box 12511, Egypt.
Mona Hassan AbdelhamidClinical Research Department at Giza Health Affairs Directorate, Ministry of Health and Population, Giza P.O. Box 12511, Egypt.
Heba Ahmed GoudClinical Research Department at Giza Health Affairs Directorate, Ministry of Health and Population, Giza P.O. Box 12511, Egypt.
Rana Ragab MohamedClinical Research Department at Giza Health Affairs Directorate, Ministry of Health and Population, Giza P.O. Box 12511, Egypt.
Menna Allah Y Nasr EldienClinical Research Department at Giza Health Affairs Directorate, Ministry of Health and Population, Giza P.O. Box 12511, Egypt.
Fahad Obaid AlotaibiForensic Medical Services Center in Riyadh, Ministry of Health, Riyadh 12271, Saudi Arabia.
Abdulaziz Ibrahim AlzareaClinical Pharmacy Department, College of Pharmacy, Jouf University, Sakaka 72388, Saudi Arabia.ORCID 0000-0003-0604-6299
Abdullah Salah AlanaziClinical Pharmacy Department, College of Pharmacy, Jouf University, Sakaka 72388, Saudi Arabia.ORCID 0000-0002-8120-4018
Nehal M EisaClinical Research Department at Giza Health Affairs Directorate, Ministry of Health and Population, Giza P.O. Box 12511, Egypt.ORCID 0000-0001-9288-1826
Abdelrahman Sh RefaeeClinical Research Department at Giza Health Affairs Directorate, Ministry of Health and Population, Giza P.O. Box 12511, Egypt.ORCID 0000-0002-1981-9425
Ministry of Health and Population · EGJouf University · SAKafrelsheikh University · EGOctober 6 University · EGSaudi Commission for Health Specialties · SA
Funding
Deanship of Scientific Research at Jouf University DSR-2021-01-031871
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19Antibodies, Monoclonal, HumanizedCOVID-19 Drug TreatmentHospitalizationHumansIntensive Care UnitsInterleukin-6Retrospective StudiesSARS-CoV-2Antibodies, Monoclonal, HumanizedInterleukin-6tocilizumabCOVID-19cytokine release syndromein-hospital mortalityTocilizumab
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Efficacy of Tocilizumab in Management of COVID-19 Patients Admitted to Intensive Care Units: A Multicenter Retrospective Cohort Study. · full record | OpenQuestion